Condition: Pulmonary Disease, Chronic Obstructive
Intervention:
Sponsors: Portsmouth Hospitals NHS Trust; Pfizer
Not yet recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Pulmonary Disease, Chronic Obstructive
Intervention:
Sponsors: Portsmouth Hospitals NHS Trust; Pfizer
Not yet recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Modern living leads to an increase in asthma sufferers
Scientist Live Asthma is one of the most common respiratory diseases worldwide. During an asthma attack, the airways become constricted, leading to symptoms ranging from wheezing and coughing to severe shortness of breath. Severe attacks also often bring with them … |
View full post on asthma – Google News
Tools to manage Asthma exist,but not reaching many: Report
Modern Ghana 9/18/2011 10:00:26 AM – (CNS): The Global Asthma Report 2011 shows the tools to manage asthma exist but are not reaching many of the 235 million people affected. Asthma is the most common chronic disease among children and also … |
View full post on asthma – Google News
Virgin Media Music |
UK: Millions of patients set to benefit from a modern NHS
7thSpace Interactive (press release) Almost one in three of the population have a long term condition – such as asthma, heart and lung disease, arthritis, hypertension and diabetes – and half of people over the age of 60 have one. They are the biggest users of the NHS accounting for … NHS 'must change to meet demands' REFORM 'WILL SAVE THE NHS' |
View full post on asthma – Google News
Modern Medicine: Alpha-1 Testing
WMBB-TV Severe asthma, emphysema and other lung problems can be deadly, but there is a way that you might be able to stop these conditions before they start. … |
View full post on asthma – Google News
Research and Markets: Asthma: Modern Therapeutic Targets
Research and Markets has announced the addition of the “Asthma: Modern Therapeutic Targets” book to their offering.
The care of an increasing number of adult and child patients with asthma has become a major task for clinicians, and a growing concern for public health physicians and health care administrators. At the same time, and in response to this situation, a considerable effort is being made in basic and clinical research to develop new treatments. This book looks into the future and assesses the possibilities of a number of new therapies for asthma under exploration and development. A group of distinguished international authors examine the potential of new agents working on various targets that are currently under evaluation, including autocoids and their inhibitors, enzyme-inhibitors, sensory nerves and sensory neuropeptides, and receptors in immunology Asthma: Modern Therapeutic Targets provides physicians with an appreciation of the future directions of treatment. It provides clinical pharmacologists and researchers with an up-to-date insight into advances in this exciting field. This book will also be a valuable tool for researchers in the pharmaceutical industry.
Benefits:
* Presents a comprehensive review of current treatment options
* Latest guidelines on clinical management reviewed from an international perspective
* Provides background on pharmacology and mechanisms of drug action
* Provides a key resource for individual patient care
Readership:
* Specialists in respiratory medicine, allergy and immunology
* General physicians
* Clinical pharmacologists
* Doctors in training
Key Topics Covered:
Section I: Autocoids and their receptors in airway diseases
* Adenosine receptors: novel molecular targets in asthma
* The role of transforming growth factors in asthma and their potential as a target for therapy
* The role of transcription factors in asthma: can we modify them for therapeutic purposes?
* Is IKK a feasible therapeutic target for allergic asthma?
Section II: Enzyme inhibitors
* Protease-activated receptors: targets for therapeutic intervention in asthma
* Nitric oxide synthase as a therapeutic target in asthma
* Metalloproteinases and asthma: untried potential for new therapeutic strategies
Section III: Sensory nerves and sensory neuropeptides
* Sensory neuropeptides as innovative targets in asthma
* Rationale for vanilloid receptor 1 antagonist-based therapies in asthma
Section IV: Receptors in immunology
* Anticytokines and cytokines as asthma therapy
* Tumour necrosis factor alpha and asthma
* Are chemokines viable targets for asthma?
* Antagonism of the chemokine receptor CCR3 as a potential therapeutic treatment for asthma
Author:
* R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy
* ST Holgate, Southampton General Hospital, Southampton, UK
For more information visit http://www.researchandmarkets.com/research/a7c5bf/asthma_modern_the
Contacts
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Financial Times |
Tate Modern closes Sunflower Seeds Exhibit due to Occupational Asthma Fears
Ashley Ainsworth The Tate Modern gallery has had to stop visitors interacting with the new Sunflower Seeds exhibition due to fears that it could lead to occupational asthma … Tate Modern closes sunflower seed exhibit to the public Don't blame the Tate Modern for putting safety first Tate Modern rethinks Sunflower Seeds show after health fears |
View full post on asthma – Google News